Cohen Investment Advisors LLC Acquires 222,560 Shares of Johnson & Johnson (NYSE:JNJ)

Cohen Investment Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1,139.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 242,090 shares of the company's stock after purchasing an additional 222,560 shares during the period. Johnson & Johnson makes up 1.0% of Cohen Investment Advisors LLC's investment portfolio, making the stock its 22nd biggest holding. Cohen Investment Advisors LLC's holdings in Johnson & Johnson were worth $40,148,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RBA Wealth Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at $217,000. Joel Isaacson & Co. LLC lifted its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after acquiring an additional 2,526 shares in the last quarter. Convergence Financial LLC raised its holdings in shares of Johnson & Johnson by 21.5% in the first quarter. Convergence Financial LLC now owns 6,200 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,099 shares during the last quarter. Capital Advisors Wealth Management LLC lifted its position in shares of Johnson & Johnson by 16.6% during the first quarter. Capital Advisors Wealth Management LLC now owns 2,731 shares of the company's stock valued at $453,000 after purchasing an additional 389 shares in the last quarter. Finally, Clarus Group Inc. increased its stake in Johnson & Johnson by 7.0% in the 1st quarter. Clarus Group Inc. now owns 4,674 shares of the company's stock valued at $775,000 after buying an additional 305 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ traded down $0.33 on Wednesday, hitting $155.59. 5,543,098 shares of the company traded hands, compared to its average volume of 8,046,125. The stock has a 50 day simple moving average of $153.63 and a 200-day simple moving average of $153.87. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market cap of $374.36 billion, a PE ratio of 17.31, a PEG ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.